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It	has	been	 reported	 that	~5%-	25%	of	 cases	of	endometrial	 carci-
noma	(EC)	or	atypical	endometrial	hyperplasia	(AH)	occur	in	women	
aged	 <40	years.1-3	 Essentially,	 the	 standard	 treatment	 for	 EC	 and	
AH	is	a	total	hysterectomy4;	however,	conservative	treatment	with	
high-	dose	medroxyprogesterone	 acetate	 (MPA)	 is	 administered	 to	
women	with	 EC	 or	 AH	who	wish	 to	 preserve	 their	 fertility	 (after	
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adequate	 informed	 consent	 has	 been	 obtained).	 The	 regression	









treatment	 as	 soon	 as	 possible	 after	MPA	 therapy.	Various	 studies	
have	reported	successful	deliveries	after	conservative	treatment.5-12 
In	addition,	some	studies	have	indicated	that	fertility	treatment	after	
conservative	 treatment	 for	 EC	 or	 AH	 results	 in	 better	 pregnancy	
outcomes,	compared	with	expectant	management5-10;	however,	the	
sample	 sizes	 of	 these	 studies	were	 small	 and	 the	 accumulation	of	











The	 initial	 pathological	diagnosis	 and	EC	or	AH	 lesion	 removal	
were	performed	using	endometrial	curettage.	If	needed,	a	hysteros-
copy,	 magnetic	 resonance	 imaging,	 and/or	 computed	 tomography	
were	added	to	rule	out	myometrial	invasion	and	distant	metastasis.	
The	increased	risk	of	disease	progression	and	recurrence	that	is	as-











fertility	 examinations	 and	 treatment	 as	 soon	 as	 possible	 after	 the	
MPA	therapy.	Holmstrom	therapy	that	involves	the	oral	administra-
tion	 of	 progestin	was	 recommended	 for	 the	 patients	who	did	 not	
wish	 to	get	pregnant.	After	 the	 fertility	examination,	conventional	
fertility	treatments	 (timed	 intercourse,	ovulation	 induction	or	con-
trolled	ovarian	stimulation,	and/or	intrauterine	insemination)	or	as-








atypia	were	mild	 and	 they	were	 allowed	 to	 receive	 treatment	 for	














As	 mentioned	 above,	 some	 studies	 have	 suggested	 that	 adminis-






out	 of	 these	 11	 patients	 received	 fertility	 treatment.6	However,	 as	
far	as	the	authors	know,	there	is	no	consistent	evidence	about	which	










received	ART	 conceived	 and	 delivered	 at	 least	 1	 child.	 In	 contrast,	
the	primary	disease	relapsed	in	25%	of	these	patients	and	this	recur-
rence	rate	was	similar	to	those	that	have	been	described	in	previous	
studies.5,6	Therefore,	 it	 is	 recommended	 that	 prompt	 and	 effective	
fertility	treatment,	 including	ART,	should	be	 initiated	 just	after	con-
servative	treatment	in	patients	with	EC	or	AH	who	want	to	become	
pregnant.	 In	addition,	 the	 relatively	high	 recurrence	 rate	of	EC	and	
AH	always	must	be	taken	into	account	when	conservative	treatment	
is considered.
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